Palforzia® (peanut [Arachis hypogaea] allergen powder-dnfp) – Expanded indication
July 26, 2024 - The FDA approved Aimmune Therapeutics Palforzia (peanut [Arachis hypogaea] allergen powder-dnfp), for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut. Palforzia is approved for use in patients with a confirmed diagnosis of peanut allergy. Initial dose escalation may be administered to patients aged 1 through 17 years. Up-dosing and maintenance may be continued in patients 1 year of age and older.